Reducing patient burden in rare disease trials: DCTs for increased patient centricity

May 14, 2025 - 06:00

Reducing patient burden in rare disease trials: DCTs for increased patient centricity

Read the original article

Tags:

Previous Article

Orphan drug market access in Europe: HTA challenges and the growing potential of...

FDA clears Ensoma’s application for rare genetic disorder treatment

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion

STAT+: Novartis to buy German biotech MorphoSys for $2....

Feb 5, 2024

Dalfampridine IR by Solaxa for Spinocerebellar Ataxia (...

Jul 6, 2024

Germany’s Ministry of Health refutes accusations of worsening market conditions

Germany’s Ministry of Health refutes accusations of wor...

Jan 31, 2024